Please assess the completion status of the following clinical trial:

Trial Title: Entecavir for Decompensated HBV Cirrhosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants with decompensated liver cirrhosis and~* Replicative HBV infection (HBsAg positive, serum HBV DNA titer \>100,000 IU/mL) regardless of HBeAg and anti-HBe test results~Exclusion Criteria:~* prior exposure to NAs or other specific treatment for HBV infection (e.g. pegylated interferon)~* hepatocellular carcinoma~* co-infection with any other hepatotropic viruses or HIV~* acute-on-chronic liver failure as defined by Asia-Pacific Association for the Study of Liver criteria~* significant alcohol intake or another concomitant hepatobiliary disease~* expected survival below 4 weeks (e.g. hemodynamic instability, active sepsis, hepatorenal syndrome, etc)~* use of immunosuppressive medication or~* portal vein thrombosis.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ETV 0.5 mg (Type: None): Group of study participants who were started on 0.5 mg/day of entecavir
- ETV 1.0 mg (Type: None): Group of study participants who were started on 1.0 mg/day of entecavir

Based on this trial design, predict the completion outcome and termination type (if applicable).